183 related articles for article (PubMed ID: 7331843)
21. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
Morasiewicz J; Baranowski P; Borys J; Jańska-Skomorowska M; Kiejna A
Psychiatr Pol; 1995; 29(3):405-20. PubMed ID: 7652093
[TBL] [Abstract][Full Text] [Related]
22. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
Viala A; Aymard N; Leyris A; Caroli F
Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
[TBL] [Abstract][Full Text] [Related]
23. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.
Goff DC; Midha KK; Brotman AW; Waites M; Baldessarini RJ
Am J Psychiatry; 1991 Jun; 148(6):790-2. PubMed ID: 2035723
[TBL] [Abstract][Full Text] [Related]
24. The use of depot neuroleptic haloperidol decanoate.
Fernando J; Krishna Raju R; Jones GG; Stanley RO
Acta Psychiatr Scand; 1984 Feb; 69(2):175-6. PubMed ID: 6702478
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
[TBL] [Abstract][Full Text] [Related]
26. [On the position of butyrophenone derivative Triperidol in psychiatric treatment].
Lange E; Scholz V
Psychiatr Neurol Med Psychol (Leipz); 1968 Jun; 20(6):202-7. PubMed ID: 5731875
[No Abstract] [Full Text] [Related]
27. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy of haloperidol in chronic psychotic patients.
Lapolla A
Int J Neuropsychiatry; 1967 Aug; 3():Suppl l:68-77. PubMed ID: 6051725
[No Abstract] [Full Text] [Related]
29. [Preliminary study corncerning the treatment of chronic psychoses with Flupenthixol decanoate].
Brasseur R
Schweiz Rundsch Med Prax; 1971 Aug; 60(33):1107-13. PubMed ID: 5562153
[No Abstract] [Full Text] [Related]
30. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Nesvåg R; Hendset M; Refsum H; Tanum L
Acta Psychiatr Scand; 2006 Jul; 114(1):21-6. PubMed ID: 16774657
[TBL] [Abstract][Full Text] [Related]
31. A butyrophenone (haloperidol) for the treatment of institutionalized patients.
Lapolla A; Nash LR
Int J Neuropsychiatry; 1966 Apr; 2(2):129-34. PubMed ID: 5335397
[No Abstract] [Full Text] [Related]
32. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients.
Viukari M; Salo H; Lamminsivu U; Gordin A
Acta Psychiatr Scand; 1982 Apr; 65(4):301-8. PubMed ID: 7080851
[TBL] [Abstract][Full Text] [Related]
33. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
34. Plasma level and effect of low-dose haloperidol in acute psychosis.
Bleeker JA; Dingemans PM; Frohn-de Winter ML; van de Slooten EP
Psychopharmacol Bull; 1984; 20(2):317-9. PubMed ID: 6728996
[No Abstract] [Full Text] [Related]
35. Acutely psychotic patients receiving high-dose haloperidol therapy.
Remington G; Pollock B; Voineskos G; Reed K; Coulter K
J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
[TBL] [Abstract][Full Text] [Related]
36. [Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Radzuweit H; Knorr W
Endokrinologie; 1969; 54(1):111-7. PubMed ID: 5358570
[No Abstract] [Full Text] [Related]
37. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.
Beresford R; Ward A
Drugs; 1987 Jan; 33(1):31-49. PubMed ID: 3545764
[TBL] [Abstract][Full Text] [Related]
38. A controlled evaluation of haloperidol, chlorpromazine, and sodium amobarbital: intramuscular short-term use in acute psychotic patients.
Shopsin B; Hekimian LJ; Gershon S; Floyd A
Curr Ther Res Clin Exp; 1969 Sep; 11(9):561-73. PubMed ID: 4980886
[No Abstract] [Full Text] [Related]
39. [Clinical experience with fluphenazine decanoate in psychoses].
Náhunek K; Rodová A; Svestka J
Act Nerv Super (Praha); 1970 Jan; 12(1):47-9. PubMed ID: 5460564
[No Abstract] [Full Text] [Related]
40. Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia.
Meco G; Falaschi P; Casacchia M; Rocco A; Petrini P; Rosa M; Agnoli A
Adv Biochem Psychopharmacol; 1985; 40():89-93. PubMed ID: 4025041
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
